Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents.


There is a very great pharmacologic advantage to the intraperitoneal administration of many agents active against human ovarian carcinoma. In principle, the use of a systemic neutralizing agent can further improve the therapeutic index of this approach. In the case of the cell cycle phase-specific antimetabolite methotrexate, systemic administration of… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics